Evidence map›Paper›PMID 40294999›Full record

Observational studyIn vivo (Athens, Greece)

Factors for Discontinuation of Naldemedine Therapy in a Palliative Ward.

Takaki Kanie, Tomohiro Mizuno, Takenao Koseki, Aya Hanamoto, Hiroko Sawano, Masako Tomida, Yukiko Kakumae, Takahiro Hayashi, Hiroshi Matsuoka, Masanobu Usui and 1 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takaki Kanie *Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan.
Tomohiro Mizuno *Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan; tomohiro.mizuno@fujita-hu.ac.jp.
Takenao KosekiDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan.
Aya HanamotoCollege of Pharmacy, Kinjo Gakuin University, Nagoya, Japan.
Hiroko SawanoCollege of Pharmacy, Kinjo Gakuin University, Nagoya, Japan.
Masako TomidaCollege of Pharmacy, Kinjo Gakuin University, Nagoya, Japan.
Yukiko KakumaeDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan.
Takahiro HayashiDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan.
Hiroshi MatsuokaDepartment of Surgery, Fujita Health University School of Medicine, Toyoake, Japan.
Masanobu UsuiDepartment of Palliative Medicine, Fujita Health University Hospital, Toyoake, Japan.
Shigeki YamadaDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimOpioid-induced constipation (OIC) is a common adverse drug event in patients undergoing chronic pain therapy. Naldemedine is an oral, peripherally acting μ-opioid receptor antagonist that improves bowel movement without affecting opioid pain relief. In palliative wards, many patients experience malnutrition caused by cachexia and systemic inflammation because of cancer progression. We investigated whether the C-reactive protein-to-albumin ratio (CAR) affects the continuation of naldemedine therapy in a palliative ward. PATIENTS AND

methodsWe included Japanese patients in the palliative ward of Fujita Health University Hospital between April 2020 and August 2023 in this retrospective observational study. The log-rank test was used to compare the continuation rates of naldemedine over 14 days. Cox proportional hazards analysis was performed using the terms morphine-equivalent daily dose <30 mg and CAR ≥0.888.

resultsEighty patients were divided into continuation (n=58) and discontinuation (n=22) groups. The proportion of patients with a CAR ≥0.888 was significantly higher in the discontinuation group than in the continuation group (

conclusionA high CAR (≥0.888) was a risk factor for the discontinuation of naldemedine therapy in a palliative ward. Our results suggest that physicians and pharmacists should monitor CAR as a marker of malnutrition and systemic inflammation before initiating naldemedine therapy.

Indexed as

NaltrexoneNarcotic AntagonistsOpioid-Induced ConstipationPalliative CareAgedAged, 80 and overAnalgesics, OpioidC-Reactive ProteinFemaleHumansMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesAnalgesics, OpioidC-Reactive ProteinnaldemedineNaltrexoneNarcotic AntagonistsC-reactive protein-to-albumin ratioNaldemedineopioid-induced constipationpalliative ward

Identifiers

PMID40294999
PMCPMC12042015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.